As healthcare systems prepare for the coming wave of rare disease treatments often carrying high list prices, and industry braces for restrictive practices passing more costs along to patients, drug developers can help speed orphan medicines to those who need them most by better communicating value to payers and other stakeholders.
In this collaborative piece, Meg Alexander, Managing Director of our Reputation & Risk Management practice and Susan Suponcic, Managing Director of our Pricing and Market Access practice, highlight misalignments in perception that derail access to orphan drugs.
